1WZY

Crystal structure of human ERK2 complexed with a pyrazolopyridazine derivative


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.50 Å
  • R-Value Free: 0.292 
  • R-Value Work: 0.249 
  • R-Value Observed: 0.253 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.4 of the entry. See complete history


Literature

Crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative

Kinoshita, T.Warizaya, M.Ohori, M.Sato, K.Neya, M.Fujii, T.

(2006) Bioorg Med Chem Lett 16: 55-58

  • DOI: https://doi.org/10.1016/j.bmcl.2005.09.055
  • Primary Citation of Related Structures:  
    1WZY

  • PubMed Abstract: 

    A series of pyrazolopyridazine compounds were briefly investigated as ERK2 inhibitors. The crystal structure of ERK2 complexed with an allyl derivative was determined. The compound induces structural change including movement of the glycine-rich loop and peptide flip between Met108-Glu109. As a result, the newly formed subsite can recognize small hydrophobic substituents but not hydrophilic ones.


  • Organizational Affiliation

    Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd, 5-2-3 Tokodai, Tsukuba, Ibaraki 300-2698, Japan. kinotk@b.s.osakafu-u.ac.jp


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Mitogen-activated protein kinase 1368Homo sapiensMutation(s): 0 
EC: 2.7.1.37
UniProt & NIH Common Fund Data Resources
Find proteins for P28482 (Homo sapiens)
Explore P28482 
Go to UniProtKB:  P28482
PHAROS:  P28482
GTEx:  ENSG00000100030 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP28482
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
F29
Query on F29

Download Ideal Coordinates CCD File 
B [auth A]1-ALLYL-5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
C21 H17 N7
WHPQRPGHYADIAQ-UHFFFAOYSA-N
Binding Affinity Annotations 
IDSourceBinding Affinity
F29 BindingDB:  1WZY IC50: 560 (nM) from 1 assay(s)
PDBBind:  1WZY IC50: 560 (nM) from 1 assay(s)
Binding MOAD:  1WZY IC50: 560 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.50 Å
  • R-Value Free: 0.292 
  • R-Value Work: 0.249 
  • R-Value Observed: 0.253 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 48.599α = 90
b = 68.541β = 110.27
c = 59.833γ = 90
Software Package:
Software NamePurpose
CNXrefinement
CrystalCleardata scaling
CNXphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2005-12-20
    Type: Initial release
  • Version 1.1: 2008-04-30
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Version format compliance
  • Version 1.3: 2017-10-11
    Changes: Refinement description
  • Version 1.4: 2024-03-13
    Changes: Data collection, Database references, Derived calculations